Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NEUROMUSCULAR DISEASE

New insights into very-late-onset myasthenia gravis

Nature Reviews Neurology volume 16, pages 299–300 (2020)Cite this article

Subjects

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that has proved difficult to study owing to its rarity. A recent report from a large Spanish registry has provided new insights into the clinical features and management of MG, particularly in individuals aged ≥65 years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Breiner, A. et al. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul. Disord. 26, 41–46 (2016).

    Article  Google Scholar 

  2. Gurwitz, J. H. et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107–1116 (2003).

    Article  Google Scholar 

  3. Cortés-Vicente, E. et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology https://doi.org/10.1212/WNL.0000000000008903 (2020).

    Article  PubMed  Google Scholar 

  4. Guastafierro, E. et al. Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology https://doi.org/10.1159/000506310 (2020).

    Article  PubMed  Google Scholar 

  5. Cutter, G. et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve 60, 707–715 (2019).

    Article  Google Scholar 

  6. Pedersen, E. G. et al. Myasthenia and risk of cancer: a population-based case-control study. Eur. J. Neurol. 21, 773–778 (2014).

    Article  CAS  Google Scholar 

  7. McGurgan, I. J. & McGuigan, C. Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients. Brain Behav. 5, e00396 (2015).

    Article  Google Scholar 

  8. Kolb, N. A. et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve 58, 10–22 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, ON, Canada

    Carolina Barnett & Vera Bril

Authors
  1. Carolina Barnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vera Bril
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vera Bril.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barnett, C., Bril, V. New insights into very-late-onset myasthenia gravis. Nat Rev Neurol 16, 299–300 (2020). https://doi.org/10.1038/s41582-020-0345-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-020-0345-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing